Lithium treatment and human hippocampal neurogenesis.
Alish B PalmosRodrigo R R DuarteDemelza M SmeethErin C HedgesDouglas F NixonSandrine ThuretTimothy R PowellPublished in: Translational psychiatry (2021)
Lithium is a first-line treatment for bipolar disorder, where it acts as a mood-stabilizing agent. Although its precise mechanism remains unclear, neuroimaging studies have shown that lithium accumulates in the hippocampus and that chronic use amongst bipolar disorder patients is associated with larger hippocampal volumes. Here, we tested the chronic effects of low (0.75 mM) and high (2.25 mM) doses of lithium on human hippocampal progenitor cells and used immunocytochemistry to investigate the effects of lithium on cell parameters implicated in neurogenesis. Corresponding RNA-sequencing and gene-set enrichment analyses were used to evaluate whether genes affected by lithium in our model overlap with those regulating the volume of specific layers of the dentate gyrus. We observed that high-dose lithium treatment in human hippocampal progenitors increased the generation of neuroblasts (P ≤ 0.01), neurons (P ≤ 0.01), and glia (P ≤ 0.001), alongside the expression of genes, which regulate the volume of the molecular layer of the dentate gyrus. This study provides empirical support that adult hippocampal neurogenesis and gliogenesis are mechanisms that could contribute to the effects of lithium on human hippocampal volume.
Keyphrases
- bipolar disorder
- cerebral ischemia
- endothelial cells
- solid state
- high dose
- induced pluripotent stem cells
- pluripotent stem cells
- major depressive disorder
- genome wide
- single cell
- poor prognosis
- subarachnoid hemorrhage
- gene expression
- brain injury
- dna methylation
- ejection fraction
- mesenchymal stem cells
- temporal lobe epilepsy
- long non coding rna
- copy number
- bone marrow
- replacement therapy
- stem cell transplantation
- cognitive impairment
- case control
- patient reported
- drug induced